Page 247 of 286 · 8,574 total

patent instituted

Ericsson Inc. et al. v.Pegasus Wireless Innovation LLC

· IPR2025-00083

The PTAB instituted an IPR challenging Pegasus Wireless Innovation LLC's patent (No. 10638463) for obviousness over prior art including Takeda, Yan, and 3GPP R1-1711853. The petitioner group, comprising major wireless carriers and tech companies, successfully argued that the claimed method is unpatentable in 5G NR resource allocation.

patent denied

Ericsson Inc. et al. v.Pegasus Wireless Innovation LLC

· IPR2025-00084

The PTAB denied institution for an IPR concerning Pegasus Wireless Innovation LLC's patent, citing the proximity and significant investment in related district court proceedings. This decision emphasizes efficiency considerations under Fintiv factors when parallel litigation is active.

patent denied

Apple Inc. v.Proxense, LLC

· IPR2025-00074

The PTAB denied Apple's IPR against Proxense because a related review of the same patent had already been instituted in another proceeding.

patent instituted

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00070

CrowdStrike successfully secured institution of IPR against GoSecure's patent 9,954,872. The Board adopted a broad construction for the key term 'association,' reinforcing the likelihood of unpatentability.

patent instituted

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00070

CrowdStrike initiated an IPR against GoSecure's '872 patent, focusing on obviousness (103) in the field of Intrusion Detection Systems. The Board found a reasonable likelihood of success for Ground 1 regarding Claim 1 over Capalik, advancing the case toward trial.

patent

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00070

The Director granted review of an institution decision in a patent dispute between CrowdStrike and GoSecure. The case is now remanded to the PTAB to determine which petition, if any, should proceed after claim construction.

patent denied

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00069

The PTAB denied institution of IPR for CrowdStrike against GoSecure, finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing on its obviousness grounds.

patent denied

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00068

The PTAB denied institution of IPR for CrowdStrike against GoSecure, finding that the correct claim construction was already established in a related proceeding.

patent instituted

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00068

CrowdStrike successfully petitioned to institute IPR proceedings against GoSecure regarding network intrusion detection methods. The Board adopted a broad claim construction for IDS/IPS systems, finding reasonable likelihood of obviousness over Capalik and King.

patent

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00068

The Director granted review of the institution decision in a dispute between CrowdStrike and GoSecure, vacating the initial orders. The case is remanded for the Board to determine which claim construction (broader or narrower) should be used before deciding on trial.

patent denied

Liberty Energy Inc. et al. v.U.S. WELL SERVICES, LLC et al.

· IPR2025-00066

The PTAB denied the petition to challenge claims 1-20 of patent 10598258, finding that the petitioner failed to demonstrate a reasonable likelihood of unpatentability under 35 U.S.C. § 103. The Board rejected arguments regarding obviousness, noting insufficient motivation to combine prior art references in the claimed manner.

patent denied

CrowdStrike, Inc. et al. v.GoSecure, Inc.

· IPR2025-00067

The PTAB denied CrowdStrike's IPR against GoSecure's patent, finding no reasonable likelihood of success on the grounds of obviousness. The Board specifically rejected the petitioner's argument that prior art taught fingerprint generation within a virtual machine monitor.

patent denied

Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC

· IPR2025-00065

Samsung Electronics' IPR challenge against SiOnyx, LLC was denied by the PTAB due to significant overlap with parallel district court litigation. The Board exercised its discretion under Fintiv guidance, prioritizing efficiency over the merits of the invalidity arguments.

patent denied

Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC

· IPR2025-00064

The PTAB denied Samsung Electronics' IPR petition against SiOnyx, LLC due to significant overlap with a parallel district court case. The Board found that the proximity of the trial date and overlapping issues outweighed the Petitioner’s strong merits arguments regarding anticipation and obviousness in semiconductor technology.

patent instituted

Google LLC et al. v.Multifold International Incorporated Pte. Ltd.

· IPR2025-00061

Google and Motorola Mobility successfully had their patentability challenge instituted against Multifold International's '007 patent. The Board found a reasonable likelihood of prevailing on Claim 1 based on prior art references Purcell and Nicholas, advancing the dispute to trial.

patent instituted

Google LLC et al. v.Multifold International Incorporated Pte. Ltd.

· IPR2025-00060

The PTAB instituted an IPR challenging U.S. Patent No. 8,842,080 B2 based on anticipation and obviousness grounds. Petitioner successfully argued that prior art references (Ogawa, Yook et al., Choi) render the patent claims unpatentable. The case is now set for trial.

patent instituted

Google LLC et al. v.Multifold International Incorporated Pte. Ltd.

· IPR2025-00059

Google LLC successfully petitioned to challenge Multifold International's patent 9141135 on grounds of obviousness (103). The PTAB institution decision adopted a broader claim construction for 'displays information selectively across the annunciator window,' allowing the case to proceed to trial.

patent denied

Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.

· IPR2025-00057

Amazon's IPR petition against B.S.D. Crown, Ltd. was denied after the Board maintained its finding that Petitioner lacked a reasonable likelihood of prevailing on the merits. The denial hinged on the Board adopting a conjunctive construction for key claim terms and finding no prior art disclosed all necessary components.

patent instituted

Google LLC et al. v.Multifold International Incorporated Pte. Ltd.

· IPR2025-00058

Google and Motorola challenged Multifold's patent on user interface technology based on anticipation and obviousness. The PTAB institution decision found a reasonable likelihood that at least one claim was unpatentable, moving the case toward trial.

patent denied

Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.

· IPR2025-00057

Amazon's request for Director Review regarding the institution denial of patent 8934887 was denied. Although the Board misapprehended one figure, the Panel upheld the conjunctive claim construction based on the full intrinsic record.

patent denied

Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.

· IPR2025-00057

Amazon's attempt to invalidate B.S.D. Crown's '887 patent failed before the PTAB, with the Board denying the IPR petition. The denial hinged on Amazon failing to adequately address a key claim construction—the conjunctive nature of an element related to hardware action.

patent

Amazon.com, Inc. et al. v.B.S.D. Crown, Ltd.

· IPR2025-00057

The Director granted review and vacated the denial of institution in an Amazon v. B.S.D. Crown IPR, remanding the case for further proceedings to resolve a disputed claim term.

patent instituted

Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP

· IPR2025-00056

Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'

patent instituted

Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP

· IPR2025-00055

Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.

patent instituted

Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP

· IPR2025-00054

Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.

patent denied

Arthrex, Inc. et al. v.Medshape, Inc.

· IPR2025-00053

The PTAB denied Arthrex's IPR petition against Medshape's patent (7985222), citing the complex and overlapping nature of co-pending district court litigation.

patent instituted

Amazon.com, Inc. et al. v.NL Giken Inc.

· IPR2025-00050

Amazon successfully challenged NL Giken's patent (US 10880592) in the PTAB, leading to institution on claims 1-3 and 5. The petitioner argued that prior art references Walker and Chang rendered the claims obvious in the context of digital broadcasting systems.

patent instituted

Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP

· IPR2025-00052

Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.

patent denied

Innolux Corporation v.Phenix Longhorn, LLC

· IPR2025-00044

The PTAB denied the IPR petition filed by Innolux Corporation against Phenix Longhorn, LLC regarding LCD Gamma Correction technology. The denial was based primarily on Petitioner's failure to properly construct 'means-plus-function' limitations under 35 U.S.C. § 112 ¶ 6.

patent denied

Digital Global Systems, Inc. v.DeepSig Inc.

· IPR2025-00049

The PTAB denied Digital Global Systems' IPR against DeepSig Inc.'s patent, finding the petitioner failed to show a reasonable likelihood of prevailing on obviousness grounds.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →